The two properties strengthen the Company's presence in Illinois, where it currently owns and manages three other properties.

A look at Exact Sciences Corporation’s acquisition by Abbott: review EXAS revenue growth, margins, and CRC/MRD screening ...

Buy Abbott: defensive compounder with recurring cash flow. Libre diabetes devices drive growth; 2025 guidance reaffirmed.

Over the past six months, Abbott Laboratories’s shares (currently trading at $125.45) have posted a disappointing 7.9% loss, ...

Abbott (ABT) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Goski is now pursuing claims under the Americans with Disabilities Act, the Family and Medical Leave Act, and the Age ...

Over the past few years, Abbott Laboratories' (NYSE: ABT) business has been a bit of a roller coaster. The pandemic disrupted its medical device business, but it was later able to smooth out those ...

Abbott Laboratories (NYSE:ABT) on Wednesday reported first-quarter sales of $10.36 billion, up 7.2% year over year, almost in line with the consensus of $10.40 billion. First-quarter sales increased 4 ...

Abbott Laboratories must pay $495 million in damages in the case of a girl who developed a serious gastrointestinal disease as a premature infant after consuming Abbott formula, a Missouri jury ...

A St. Louis judge has granted a new trial in a case Abbott Laboratories won in the fall, in which a mother alleged that the company’s cow’s milk-based products for premature infants contributed to her ...

Abbott's (NYSE: ABT) newest sensor-based glucose technology, the FreeStyle Libre 3 Plus* sensor, is now publicly funded in ...

The two properties strengthen the Company's presence in Illinois, where it currently owns and manages three other properties.